Table 1. Basic characteristics of the patients and their correlation with CD24 expression.
| All | CD24-high | CD24-low | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 747 | n = 213 (28.5%) | n = 534 (71.5%) | |||||||
| No. | (%) | No. | (%) | No. | (%) | ||||
| Age | Median (range) | 47.16 (23.84–81.21) | 48.08 (24.08–80.48) | 46.80 (23.84–81.21) | |||||
| 0.139 | |||||||||
| <50 | 447 | 59.8% | 118 | 26.4% | 329 | 73.6% | |||
| ≥50 | 300 | 40.2% | 95 | 31.7% | 205 | 68.3% | |||
| Tumour size | 0.056 | ||||||||
| 0–2 | 300 | 40.2% | 71 | 23.7% | 229 | 76.3% | |||
| 2.1–5 | 396 | 53.0% | 127 | 32.1% | 269 | 67.9% | |||
| ≥5.1 | 51 | 6.8% | 15 | 29.4% | 36 | 70.6% | |||
| pT | 0.059 | ||||||||
| 1 | 298 | 39.9% | 71 | 23.8% | 227 | 76.2% | |||
| 2 | 396 | 53.0% | 127 | 32.1% | 269 | 67.9% | |||
| 3–4 | 53 | 7.1% | 15 | 28.3% | 38 | 71.7% | |||
| LN metastasis | <0.001 | ||||||||
| Negative | 400 | 53.5% | 93 | 23.3% | 307 | 76.8% | |||
| Positive | 347 | 46.5% | 120 | 34.6% | 227 | 65.4% | |||
| pN | 0.006 | ||||||||
| 0 | 400 | 53.5% | 93 | 23.3% | 307 | 76.8% | |||
| 1 | 184 | 24.6% | 62 | 33.7% | 122 | 66.3% | |||
| 2 | 84 | 11.2% | 32 | 38.1% | 52 | 61.9% | |||
| 3 | 79 | 10.6% | 26 | 32.9% | 53 | 67.1% | |||
| Pathologic stage | 0.020 | ||||||||
| I | 194 | 26.0% | 42 | 21.6% | 152 | 78.4% | |||
| II | 377 | 50.5% | 110 | 29.2% | 267 | 70.8% | |||
| III | 176 | 23.6% | 61 | 34.7% | 115 | 65.3% | |||
| Histologic grade | 0.187 | ||||||||
| 1 | 83 | 11.1% | 17 | 20.5% | 66 | 79.5% | |||
| 2 | 269 | 36.0% | 83 | 30.9% | 186 | 69.1% | |||
| 3 | 341 | 45.6% | 97 | 28.4% | 244 | 71.6% | |||
| Unknown | 54 | 7.2% | 16 | 29.6% | 38 | 70.4% | |||
| Nuclear grade | 0.642 | ||||||||
| 1 | 72 | 9.6% | 17 | 23.6% | 55 | 76.4% | |||
| 2 | 365 | 48.9% | 106 | 29.0% | 259 | 71.0% | |||
| 3 | 284 | 38.0% | 81 | 28.5% | 203 | 71.5% | |||
| Unknown | 26 | 3.5% | 9 | 34.6% | 17 | 65.4% | |||
| Chemotherapy | 0.337 | ||||||||
| No | 93 | 12.4% | 31 | 33.3% | 62 | 66.7% | |||
| Yes | 652 | 87.3% | 182 | 27.9% | 470 | 72.1% | |||
| Unknown | 2 | 0.3% | 0 | 0.0% | 2 | 100.0% | |||
| Radiotherapy | 0.601 | ||||||||
| No | 295 | 39.5% | 88 | 29.8% | 207 | 70.2% | |||
| Yes | 450 | 60.2% | 125 | 27.8% | 325 | 72.2% | |||
| Unknown | 2 | 0.3% | 0 | 0.0% | 2 | 100.0% | |||
| Hormone therapy | 0.197 | ||||||||
| No | 285 | 38.2% | 73 | 25.6% | 212 | 74.4% | |||
| Yes | 452 | 60.5% | 137 | 30.3% | 315 | 69.7% | |||
| Unknown | 10 | 1.3% | 3 | 30.0% | 7 | 70.0% | |||
| EIC | 0.332 | ||||||||
| Negative | 365 | 48.9% | 102 | 27.9% | 263 | 72.1% | |||
| Positive | 162 | 21.7% | 38 | 23.5% | 124 | 76.5% | |||
| Unknown | 220 | 29.5% | 73 | 33.2% | 147 | 66.8% | |||
| p53 | 0.598 | ||||||||
| Negative | 292 | 39.1% | 83 | 28.4% | 209 | 71.6% | |||
| Positive | 343 | 45.9% | 90 | 26.2% | 253 | 73.8% | |||
| Unknown | 112 | 15.0% | 40 | 35.7% | 72 | 64.3% | |||
| ER | 0.638 | ||||||||
| Negative | 300 | 40.2% | 89 | 29.7% | 211 | 70.3% | |||
| Positive | 446 | 59.7% | 124 | 27.8% | 322 | 72.2% | |||
| Unknown | 1 | 0.1% | 0 | 0.0% | 1 | 100.0% | |||
| PR | 0.305 | ||||||||
| Negative | 414 | 55.4% | 125 | 30.2% | 289 | 69.8% | |||
| Positive | 332 | 44.4% | 88 | 26.5% | 244 | 73.5% | |||
| Unknown | 1 | 0.1% | 0 | 0.0% | 1 | 100.0% | |||
| HER2 | 0.047 | ||||||||
| Negative | 545 | 73.0% | 144 | 26.4% | 401 | 73.6% | |||
| Positive | 202 | 27.0% | 69 | 34.2% | 133 | 65.8% | |||
| EGFR | 0.940 | ||||||||
| Negative | 690 | 92.4% | 196 | 28.4% | 494 | 71.6% | |||
| Positive | 57 | 7.6% | 17 | 29.8% | 40 | 70.2% | |||
| CK5/6 | 0.318 | ||||||||
| Negative | 688 | 92.1% | 200 | 29.1% | 488 | 70.9% | |||
| Positive | 59 | 7.9% | 13 | 22.0% | 46 | 78.0% | |||
| Subtype (4 subtypes) | 0.041 | ||||||||
| Luminal A | 362 | 48.5% | 102 | 28.2% | 260 | 71.8% | |||
| Luminal B | 101 | 13.5% | 30 | 29.7% | 71 | 70.3% | |||
| HER2 | 100 | 13.4% | 39 | 39.0% | 61 | 61.0% | |||
| TNBC | 183 | 24.5% | 42 | 23.0% | 141 | 77.0% | |||
| Unknown | 1 | 0.1% | 0 | 0.0% | 1 | 100.0% | |||
| Subtype (5 subtypes) | 0.067 | ||||||||
| Luminal A | 362 | 48.5% | 102 | 28.2% | 260 | 71.8% | |||
| Luminal B | 101 | 13.5% | 30 | 29.7% | 71 | 70.3% | |||
| HER2 | 100 | 13.4% | 39 | 39.0% | 61 | 61.0% | |||
| Basal | 66 | 8.8% | 13 | 19.7% | 53 | 80.3% | |||
| QNBC | 117 | 15.7% | 29 | 24.8% | 88 | 75.2% | |||
| Unknown | 1 | 0.1% | 0 | 0.0% | 1 | 100.0% | |||
Abbreviations: LN, lymph node; EIC, extensive intraductal component; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; CK5/6, cytokeratin 5/6; TNBC, triple-negative breast cancer, QNBC, quintuple-negative breast cancer. P values less than 0.05 are marked in bold.